{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T09:54:50Z","timestamp":1782813290588,"version":"3.54.5"},"reference-count":119,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,4,28]],"date-time":"2017-04-28T00:00:00Z","timestamp":1493337600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s00467-017-3672-x","type":"journal-article","created":{"date-parts":[[2017,4,28]],"date-time":"2017-04-28T07:18:36Z","timestamp":1493363916000},"page":"395-408","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children?"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0981-8621","authenticated-orcid":false,"given":"Peter","family":"Janssens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Weydert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"De Rechter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl Martin","family":"Wissing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max Christoph","family":"Liebau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djalila","family":"Mekahli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,28]]},"reference":[{"key":"3672_CR1","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1681\/ASN.2009020162","volume":"20","author":"M Barua","year":"2009","unstructured":"Barua M, Cil O, Paterson AD, Wang K, He N, Dicks E, Parfrey P, Pei Y (2009) Family history of renal disease severity predicts the mutated gene in ADPKD. J Am Soc Nephrol 20:1833\u20131838","journal-title":"J Am Soc Nephrol"},{"key":"3672_CR2","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.ajhg.2016.05.004","volume":"98","author":"B Porath","year":"2016","unstructured":"Porath B, Gainullin VG, Cornec-Le Gall E, Dillinger EK, Heyer CM, Hopp K, Edwards ME, Madsen CD, Mauritz SR, Banks CJ, Baheti S, Reddy B, Herrero JI, Banales JM, Hogan MC, Tasic V, Watnick TJ, Chapman AB, Vigneau C, Lavainne F, Audrezet MP, Ferec C, Le Meur Y, Torres VE, Genkyst Study Group, HALT Progression of Polycystic Kidney Disease Group; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease, Harris PC (2016) Mutations in GANAB, encoding the glucosidase IIalpha subunit, cause autosomal-dominant polycystic kidney and liver disease. Am J Hum Genet 98:1193\u20131207","journal-title":"Am J Hum Genet"},{"key":"3672_CR3","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/humu.22708","volume":"35","author":"E Cornec-Le Gall","year":"2014","unstructured":"Cornec-Le Gall E, Audrezet MP, Le Meur Y, Chen JM, Ferec C (2014) Genetics and pathogenesis of autosomal dominant polycystic kidney disease: 20 years on. Hum Mutat 35:1393\u20131406","journal-title":"Hum Mutat"},{"key":"3672_CR4","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1038\/ki.2008.485","volume":"74","author":"MB Consugar","year":"2008","unstructured":"Consugar MB, Wong WC, Lundquist PA, Rossetti S, Kubly VJ, Walker DL, Rangel LJ, Aspinwall R, Niaudet WP, Ozen S, David A, Velinov M, Bergstralh EJ, Bae KT, Chapman AB, Guay-Woodford LM, Grantham JJ, Torres VE, Sampson JR, Dawson BD, Harris PC, CRISP Consortium (2008) Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1\/TSC2 contiguous gene syndrome. Kidney Int 74:1468\u20131479","journal-title":"Kidney Int"},{"key":"3672_CR5","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1681\/ASN.2008080882","volume":"20","author":"RW Schrier","year":"2009","unstructured":"Schrier RW (2009) Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 20:1888\u20131893","journal-title":"J Am Soc Nephrol"},{"key":"3672_CR6","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMcp0804458","volume":"359","author":"JJ Grantham","year":"2008","unstructured":"Grantham JJ (2008) Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med 359:1477\u20131485","journal-title":"N Engl J Med"},{"key":"3672_CR7","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1007\/s00467-012-2384-5","volume":"28","author":"D Mekahli","year":"2013","unstructured":"Mekahli D, Bacchetta J (2013) From bone abnormalities to mineral metabolism dysregulation in autosomal dominant polycystic kidney disease. Pediatr Nephrol 28:2089\u20132096","journal-title":"Pediatr Nephrol"},{"key":"3672_CR8","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.jpeds.2014.06.015","volume":"165","author":"LM Guay-Woodford","year":"2014","unstructured":"Guay-Woodford LM, Bissler JJ, Braun MC, Bockenhauer D, Cadnapaphornchai MA, Dell KM, Kerecuk L, Liebau MC, Alonso-Peclet MH, Shneider B, Emre S, Heller T, Kamath BM, Murray KF, Moise K, Eichenwald EE, Evans J, Keller RL, Wilkins-Haug L, Bergmann C, Gunay-Aygun M, Hooper SR, Hardy KK, Hartung EA, Streisand R, Perrone R, Moxey-Mims M (2014) Consensus expert recommendations for the diagnosis and management of autosomal recessive polycystic kidney disease: report of an international conference. J Pediatr 165:611\u2013617","journal-title":"J Pediatr"},{"key":"3672_CR9","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1007\/s00467-012-2370-y","volume":"28","author":"MC Liebau","year":"2013","unstructured":"Liebau MC, Serra AL (2013) Looking at the (w)hole: magnet resonance imaging in polycystic kidney disease. Pediatr Nephrol 28:1771\u20131783","journal-title":"Pediatr Nephrol"},{"key":"3672_CR10","unstructured":"Sweeney WE, Avner ED (1993) Polycystic Kidney Disease, Autosomal Recessive. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Ledbetter N, Mefford HC, Smith RJH, Stephens K (eds) GeneReviews(R), Seattle (WA)"},{"key":"3672_CR11","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/j.1523-1755.2005.00148.x","volume":"67","author":"C Bergmann","year":"2005","unstructured":"Bergmann C, Senderek J, Windelen E, Kupper F, Middeldorf I, Schneider F, Dornia C, Rudnik-Schoneborn S, Konrad M, Schmitt CP, Seeman T, Neuhaus TJ, Vester U, Kirfel J, Buttner R, Zerres K, Arbeitsgemeinschaft f\u00fcr P\u00e4diatrische Nephrologie (2005) Clinical consequences of PKHD1 mutations in 164 patients with autosomal-recessive polycystic kidney disease (ARPKD). Kidney Int 67:829\u2013848","journal-title":"Kidney Int"},{"key":"3672_CR12","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/MPG.0b013e318228330c","volume":"54","author":"K O\u2019Brien","year":"2012","unstructured":"O\u2019Brien K, Font-Montgomery E, Lukose L, Bryant J, Piwnica-Worms K, Edwards H, Riney L, Garcia A, Daryanani K, Choyke P, Mohan P, Heller T, Gahl WA, Gunay-Aygun M (2012) Congenital hepatic fibrosis and portal hypertension in autosomal dominant polycystic kidney disease. J Pediatr Gastroenterol Nutr 54:83\u201389","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"3672_CR13","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/ajmg.c.30225","volume":"151C","author":"M Gunay-Aygun","year":"2009","unstructured":"Gunay-Aygun M (2009) Liver and kidney disease in ciliopathies. Am J Med Genet C Semin Med Genet 151C:296\u2013306","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"3672_CR14","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1681\/ASN.2008010033","volume":"19","author":"JY Kaimori","year":"2008","unstructured":"Kaimori JY, Germino GG (2008) ARPKD and ADPKD: first cousins or more distant relatives? J Am Soc Nephrol 19:416\u2013418","journal-title":"J Am Soc Nephrol"},{"key":"3672_CR15","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00467-010-1731-7","volume":"26","author":"AM Waters","year":"2011","unstructured":"Waters AM, Beales PL (2011) Ciliopathies: an expanding disease spectrum. Pediatr Nephrol 26:1039\u20131056","journal-title":"Pediatr Nephrol"},{"key":"3672_CR16","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1172\/JCI72272","volume":"124","author":"PC Harris","year":"2014","unstructured":"Harris PC, Torres VE (2014) Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease. J Clin Invest 124:2315\u20132324","journal-title":"J Clin Invest"},{"key":"3672_CR17","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1093\/hmg\/ddl404","volume":"15","author":"Y Wu","year":"2006","unstructured":"Wu Y, Dai XQ, Li Q, Chen CX, Mai W, Hussain Z, Long W, Montalbetti N, Li G, Glynne R, Wang S, Cantiello HF, Wu G, Chen XZ (2006) Kinesin-2 mediates physical and functional interactions between polycystin-2 and fibrocystin. Hum Mol Genet 15:3280\u20133292","journal-title":"Hum Mol Genet"},{"key":"3672_CR18","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1128\/MCB.00072-07","volume":"27","author":"S Wang","year":"2007","unstructured":"Wang S, Zhang J, Nauli SM, Li X, Starremans PG, Luo Y, Roberts KA, Zhou J (2007) Fibrocystin\/polyductin, found in the same protein complex with polycystin-2, regulates calcium responses in kidney epithelia. Mol Cell Biol 27:3241\u20133252","journal-title":"Mol Cell Biol"},{"key":"3672_CR19","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/hmg\/ddm141","volume":"16","author":"MA Garcia-Gonzalez","year":"2007","unstructured":"Garcia-Gonzalez MA, Menezes LF, Piontek KB, Kaimori J, Huso DL, Watnick T, Onuchic LF, Guay-Woodford LM, Germino GG (2007) Genetic interaction studies link autosomal dominant and recessive polycystic kidney disease in a common pathway. Hum Mol Genet 16:1940\u20131950","journal-title":"Hum Mol Genet"},{"key":"3672_CR20","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1681\/ASN.2010101080","volume":"22","author":"C Bergmann","year":"2011","unstructured":"Bergmann C, von Bothmer J, Ortiz Bruchle N, Venghaus A, Frank V, Fehrenbach H, Hampel T, Pape L, Buske A, Jonsson J, Sarioglu N, Santos A, Ferreira JC, Becker JU, Cremer R, Hoefele J, Benz MR, Weber LT, Buettner R, Zerres K (2011) Mutations in multiple PKD genes may explain early and severe polycystic kidney disease. J Am Soc Nephrol 22:2047\u20132056","journal-title":"J Am Soc Nephrol"},{"key":"3672_CR21","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1681\/ASN.2013040398","volume":"25","author":"VE Torres","year":"2014","unstructured":"Torres VE, Harris PC (2014) Strategies targeting cAMP signaling in treating polycystic kidney disease. J Am Soc Nephrol 25:18\u201332","journal-title":"J Am Soc Nephrol"},{"key":"3672_CR22","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1056\/NEJMra1010172","volume":"364","author":"F Hildebrandt","year":"2011","unstructured":"Hildebrandt F, Benzing T, Katsanis N (2011) Ciliopathies. N Engl J Med 364:1533\u20131543","journal-title":"N Engl J Med"},{"key":"3672_CR23","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1007\/s00467-012-2118-8","volume":"27","author":"D Wesche","year":"2012","unstructured":"Wesche D, Deen PM, Knoers NV (2012) Congenital nephrogenic diabetes insipidus: the current state of affairs. Pediatr Nephrol 27:2183\u20132204","journal-title":"Pediatr Nephrol"},{"key":"3672_CR24","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/nm935","volume":"9","author":"VH Gattone 2nd","year":"2003","unstructured":"Gattone VH 2nd, Wang X, Harris PC, Torres VE (2003) Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 9:1323\u20131326","journal-title":"Nat Med"},{"key":"3672_CR25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1681\/ASN.2013121312","volume":"26","author":"K Hopp","year":"2015","unstructured":"Hopp K, Hommerding CJ, Wang X, Ye H, Harris PC, Torres VE (2015) Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model. J Am Soc Nephrol 26:39\u201347","journal-title":"J Am Soc Nephrol"},{"key":"3672_CR26","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.2215\/CJN.03530411","volume":"6","author":"E Higashihara","year":"2011","unstructured":"Higashihara E, Torres VE, Chapman AB, Grantham JJ, Bae K, Watnick TJ, Horie S, Nutahara K, Ouyang J, Krasa HB, Czerwiec FS, TEMPOFormula and 156-05-002 Study Investigators (2011) Tolvaptan in autosomal dominant polycystic kidney disease: three years experience. Clin J Am Soc Nephrol 6:2499\u20132507","journal-title":"Clin J Am Soc Nephrol"},{"key":"3672_CR27","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS, TEMPO 3:4 Trial Investigators (2012) Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367:2407\u20132418","journal-title":"N Engl J Med"},{"key":"3672_CR28","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nrneph.2015.39","volume":"11","author":"FT Chebib","year":"2015","unstructured":"Chebib FT, Sussman CR, Wang X, Harris PC, Torres VE (2015) Vasopressin and disruption of calcium signalling in polycystic kidney disease. Nat Rev Nephrol 11:451\u2013464","journal-title":"Nat Rev Nephrol"},{"key":"3672_CR29","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1007\/s00018-012-1188-x","volume":"70","author":"D Mekahli","year":"2013","unstructured":"Mekahli D, Parys JB, Bultynck G, Missiaen L, De Smedt H (2013) Polycystins and cellular Ca2+ signaling. Cell Mol Life Sci 70:2697\u20132712","journal-title":"Cell Mol Life Sci"},{"key":"3672_CR30","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/ncb3370","volume":"18","author":"I Sanchez","year":"2016","unstructured":"Sanchez I, Dynlacht BD (2016) Cilium assembly and disassembly. Nat Cell Biol 18:711\u2013717","journal-title":"Nat Cell Biol"},{"key":"3672_CR31","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1097\/01.ASN.0000141055.57643.E0","volume":"15","author":"GJ Pazour","year":"2004","unstructured":"Pazour GJ (2004) Intraflagellar transport and cilia-dependent renal disease: the ciliary hypothesis of polycystic kidney disease. J Am Soc Nephrol 15:2528\u20132536","journal-title":"J Am Soc Nephrol"},{"key":"3672_CR32","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1681\/ASN.2005080830","volume":"17","author":"SM Nauli","year":"2006","unstructured":"Nauli SM, Rossetti S, Kolb RJ, Alenghat FJ, Consugar MB, Harris PC, Ingber DE, Loghman-Adham M, Zhou J (2006) Loss of polycystin-1 in human cyst-lining epithelia leads to ciliary dysfunction. J Am Soc Nephrol 17:1015\u20131025","journal-title":"J Am Soc Nephrol"},{"key":"3672_CR33","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1083\/jcb.200805124","volume":"182","author":"M Kottgen","year":"2008","unstructured":"Kottgen M, Buchholz B, Garcia-Gonzalez MA, Kotsis F, Fu X, Doerken M, Boehlke C, Steffl D, Tauber R, Wegierski T, Nitschke R, Suzuki M, Kramer-Zucker A, Germino GG, Watnick T, Prenen J, Nilius B, Kuehn EW, Walz G (2008) TRPP2 and TRPV4 form a polymodal sensory channel complex. J Cell Biol 182:437\u2013447","journal-title":"J Cell Biol"},{"key":"3672_CR34","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nature17426","volume":"531","author":"M Delling","year":"2016","unstructured":"Delling M, Indzhykulian AA, Liu X, Li Y, Xie T, Corey DP, Clapham DE (2016) Primary cilia are not calcium-responsive mechanosensors. Nature 531:656\u2013660","journal-title":"Nature"},{"key":"3672_CR35","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/ng.2715","volume":"45","author":"M Ma","year":"2013","unstructured":"Ma M, Tian X, Igarashi P, Pazour GJ, Somlo S (2013) Loss of cilia suppresses cyst growth in genetic models of autosomal dominant polycystic kidney disease. Nat Genet 45:1004\u20131012","journal-title":"Nat Genet"},{"key":"3672_CR36","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.krcp.2014.05.002","volume":"33","author":"SH Lee","year":"2014","unstructured":"Lee SH, Somlo S (2014) Cyst growth, polycystins, and primary cilia in autosomal dominant polycystic kidney disease. Kidney Res Clin Pract 33:73\u201378","journal-title":"Kidney Res Clin Pract"},{"key":"3672_CR37","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1093\/hmg\/ddg274","volume":"12","author":"CJ Ward","year":"2003","unstructured":"Ward CJ, Yuan D, Masyuk TV, Wang X, Punyashthiti R, Whelan S, Bacallao R, Torra R, LaRusso NF, Torres VE, Harris PC (2003) Cellular and subcellular localization of the ARPKD protein; fibrocystin is expressed on primary cilia. Hum Mol Genet 12:2703\u20132710","journal-title":"Hum Mol Genet"},{"key":"3672_CR38","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1093\/hmg\/ddm039","volume":"16","author":"JY Kaimori","year":"2007","unstructured":"Kaimori JY, Nagasawa Y, Menezes LF, Garcia-Gonzalez MA, Deng J, Imai E, Onuchic LF, Guay-Woodford LM, Germino GG (2007) Polyductin undergoes notch-like processing and regulated release from primary cilia. Hum Mol Genet 16:942\u2013956","journal-title":"Hum Mol Genet"},{"key":"3672_CR39","doi-asserted-by":"crossref","first-page":"34357","DOI":"10.1074\/jbc.M606740200","volume":"281","author":"T Hiesberger","year":"2006","unstructured":"Hiesberger T, Gourley E, Erickson A, Koulen P, Ward CJ, Masyuk TV, Larusso NF, Harris PC, Igarashi P (2006) Proteolytic cleavage and nuclear translocation of fibrocystin is regulated by intracellular Ca2+ and activation of protein kinase C. J Biol Chem 281:34357\u201334364","journal-title":"J Biol Chem"},{"key":"3672_CR40","doi-asserted-by":"crossref","first-page":"31559","DOI":"10.1074\/jbc.M805452200","volume":"283","author":"I Kim","year":"2008","unstructured":"Kim I, Li C, Liang D, Chen XZ, Coffy RJ, Ma J, Zhao P, Wu G (2008) Polycystin-2 expression is regulated by a PC2-binding domain in the intracellular portion of fibrocystin. J Biol Chem 283:31559\u201331566","journal-title":"J Biol Chem"},{"key":"3672_CR41","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1681\/ASN.2007070770","volume":"19","author":"I Kim","year":"2008","unstructured":"Kim I, Fu Y, Hui K, Moeckel G, Mai W, Li C, Liang D, Zhao P, Ma J, Chen XZ, George AL Jr, Coffey RJ, Feng ZP, Wu G (2008) Fibrocystin\/polyductin modulates renal tubular formation by regulating polycystin-2 expression and function. J Am Soc Nephrol 19:455\u2013468","journal-title":"J Am Soc Nephrol"},{"key":"3672_CR42","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/ki.1987.121","volume":"31","author":"JJ Grantham","year":"1987","unstructured":"Grantham JJ, Geiser JL, Evan AP (1987) Cyst formation and growth in autosomal dominant polycystic kidney disease. Kidney Int 31:1145\u20131152","journal-title":"Kidney Int"},{"key":"3672_CR43","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/ki.2008.686","volume":"75","author":"S Rossetti","year":"2009","unstructured":"Rossetti S, Kubly VJ, Consugar MB, Hopp K, Roy S, Horsley SW, Chauveau D, Rees L, Barratt TM, van\u2019t Hoff WG, Niaudet P, Torres VE, Harris PC (2009) Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease. Kidney Int 75:848\u2013855","journal-title":"Kidney Int"},{"key":"3672_CR44","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1681\/ASN.V1071524","volume":"10","author":"Y Pei","year":"1999","unstructured":"Pei Y, Watnick T, He N, Wang K, Liang Y, Parfrey P, Germino G, St George-Hyslop P (1999) Somatic PKD2 mutations in individual kidney and liver cysts support a \u201ctwo-hit\u201d model of cystogenesis in type 2 autosomal dominant polycystic kidney disease. J Am Soc Nephrol 10:1524\u20131529","journal-title":"J Am Soc Nephrol"},{"key":"3672_CR45","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1128\/MCB.26.4.1538-1548.2006","volume":"26","author":"C Thivierge","year":"2006","unstructured":"Thivierge C, Kurbegovic A, Couillard M, Guillaume R, Cote O, Trudel M (2006) Overexpression of PKD1 causes polycystic kidney disease. Mol Cell Biol 26:1538\u20131548","journal-title":"Mol Cell Biol"},{"key":"3672_CR46","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.devcel.2005.12.005","volume":"10","author":"SH Low","year":"2006","unstructured":"Low SH, Vasanth S, Larson CH, Mukherjee S, Sharma N, Kinter MT, Kane ME, Obara T, Weimbs T (2006) Polycystin-1, STAT6, and P100 function in a pathway that transduces ciliary mechanosensation and is activated in polycystic kidney disease. Dev Cell 10:57\u201369","journal-title":"Dev Cell"},{"key":"3672_CR47","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1681\/ASN.2013091026","volume":"25","author":"JJ Talbot","year":"2014","unstructured":"Talbot JJ, Song X, Wang X, Rinschen MM, Doerr N, LaRiviere WB, Schermer B, Pei YP, Torres VE, Weimbs T (2014) The cleaved cytoplasmic tail of polycystin-1 regulates Src-dependent STAT3 activation. J Am Soc Nephrol 25:1737\u20131748","journal-title":"J Am Soc Nephrol"},{"key":"3672_CR48","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s11102-015-0703-0","volume":"19","author":"F Rotondo","year":"2016","unstructured":"Rotondo F, Butz H, Syro LV, Yousef GM, Di Ieva A, Restrepo LM, Quintanar-Stephano A, Berczi I, Kovacs K (2016) Arginine vasopressin (AVP): a review of its historical perspectives, current research and multifunctional role in the hypothalamo-hypophysial system. Pituitary 19:345\u2013355","journal-title":"Pituitary"},{"key":"3672_CR49","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1046\/j.1523-1755.1998.00990.x","volume":"54","author":"G Yasuda","year":"1998","unstructured":"Yasuda G, Jeffries WB (1998) Regulation of cAMP production in initial and terminal inner medullary collecting ducts. Kidney Int 54:80\u201386","journal-title":"Kidney Int"},{"key":"3672_CR50","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/ki.2009.438","volume":"77","author":"X Wang","year":"2010","unstructured":"Wang X, Ward CJ, Harris PC, Torres VE (2010) Cyclic nucleotide signaling in polycystic kidney disease. Kidney Int 77:129\u2013140","journal-title":"Kidney Int"},{"key":"3672_CR51","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1681\/ASN.2013010077","volume":"25","author":"S Rees","year":"2014","unstructured":"Rees S, Kittikulsuth W, Roos K, Strait KA, Van Hoek A, Kohan DE (2014) Adenylyl cyclase 6 deficiency ameliorates polycystic kidney disease. J Am Soc Nephrol 25:232\u2013237","journal-title":"J Am Soc Nephrol"},{"key":"3672_CR52","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1681\/ASN.2015010057","volume":"27","author":"H Ye","year":"2016","unstructured":"Ye H, Wang X, Sussman CR, Hopp K, Irazabal MV, Bakeberg JL, LaRiviere WB, Manganiello VC, Vorhees CV, Zhao H, Harris PC, van Deursen J, Ward CJ, Torres VE (2016) Modulation of polycystic kidney disease severity by phosphodiesterase 1 and 3 subfamilies. J Am Soc Nephrol 27:1312\u20131320","journal-title":"J Am Soc Nephrol"},{"key":"3672_CR53","doi-asserted-by":"crossref","first-page":"10679","DOI":"10.1073\/pnas.1016214108","volume":"108","author":"YH Choi","year":"2011","unstructured":"Choi YH, Suzuki A, Hajarnis S, Ma Z, Chapin HC, Caplan MJ, Pontoglio M, Somlo S, Igarashi P (2011) Polycystin-2 and phosphodiesterase 4C are components of a ciliary A-kinase anchoring protein complex that is disrupted in cystic kidney diseases. Proc Natl Acad Sci U S A 108:10679\u201310684","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3672_CR54","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/hep.24723","volume":"55","author":"C Spirli","year":"2012","unstructured":"Spirli C, Locatelli L, Fiorotto R, Morell CM, Fabris L, Pozzan T, Strazzabosco M (2012) Altered store operated calcium entry increases cyclic 3\u2032,5\u2032-adenosine monophosphate production and extracellular signal-regulated kinases 1 and 2 phosphorylation in polycystin-2-defective cholangiocytes. Hepatology 55:856\u2013868","journal-title":"Hepatology"},{"key":"3672_CR55","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1681\/ASN.2007060688","volume":"19","author":"X Wang","year":"2008","unstructured":"Wang X, Wu Y, Ward CJ, Harris PC, Torres VE (2008) Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol 19:102\u2013108","journal-title":"J Am Soc Nephrol"},{"key":"3672_CR56","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1093\/hmg\/ddt031","volume":"22","author":"AJ Streets","year":"2013","unstructured":"Streets AJ, Wessely O, Peters DJ, Ong AC (2013) Hyperphosphorylation of polycystin-2 at a critical residue in disease reveals an essential role for polycystin-1-regulated dephosphorylation. Hum Mol Genet 22:1924\u20131939","journal-title":"Hum Mol Genet"},{"key":"3672_CR57","first-page":"180","volume":"7","author":"TJ Carroll","year":"2011","unstructured":"Carroll TJ, Das A (2011) Planar cell polarity in kidney development and disease. Organ 7:180\u2013190","journal-title":"Organ"},{"key":"3672_CR58","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1101\/gad.2008011","volume":"25","author":"JB Wallingford","year":"2011","unstructured":"Wallingford JB, Mitchell B (2011) Strange as it may seem: the many links between Wnt signaling, planar cell polarity, and cilia. Genes Dev 25:201\u2013213","journal-title":"Genes Dev"},{"key":"3672_CR59","doi-asserted-by":"crossref","first-page":"F1423","DOI":"10.1152\/ajprenal.00275.2007","volume":"293","author":"T Weimbs","year":"2007","unstructured":"Weimbs T (2007) Polycystic kidney disease and renal injury repair: common pathways, fluid flow, and the function of polycystin-1. Am J Physiol Renal Physiol 293:F1423\u2013F1432","journal-title":"Am J Physiol Renal Physiol"},{"key":"3672_CR60","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1093\/hmg\/ddp190","volume":"18","author":"H Happe","year":"2009","unstructured":"Happe H, Leonhard WN, van der Wal A, van de Water B, Lantinga-van Leeuwen IS, Breuning MH, de Heer E, Peters DJ (2009) Toxic tubular injury in kidneys from Pkd1-deletion mice accelerates cystogenesis accompanied by dysregulated planar cell polarity and canonical Wnt signaling pathways. Hum Mol Genet 18:2532\u20132542","journal-title":"Hum Mol Genet"},{"key":"3672_CR61","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1523-1755.2004.00843.x","volume":"66","author":"FA Belibi","year":"2004","unstructured":"Belibi FA, Reif G, Wallace DP, Yamaguchi T, Olsen L, Li H, Helmkamp GM Jr, Grantham JJ (2004) Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells. Kidney Int 66:964\u2013973","journal-title":"Kidney Int"},{"key":"3672_CR62","doi-asserted-by":"crossref","first-page":"40419","DOI":"10.1074\/jbc.M405079200","volume":"279","author":"T Yamaguchi","year":"2004","unstructured":"Yamaguchi T, Wallace DP, Magenheimer BS, Hempson SJ, Grantham JJ, Calvet JP (2004) Calcium restriction allows cAMP activation of the B-Raf\/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J Biol Chem 279:40419\u201340430","journal-title":"J Biol Chem"},{"key":"3672_CR63","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s00467-014-2882-8","volume":"30","author":"JJ Grantham","year":"2015","unstructured":"Grantham JJ (2015) Rationale for early treatment of polycystic kidney disease. Pediatr Nephrol 30:1053\u20131062","journal-title":"Pediatr Nephrol"},{"key":"3672_CR64","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJM199307293290503","volume":"329","author":"M Ye","year":"1993","unstructured":"Ye M, Grantham JJ (1993) The secretion of fluid by renal cysts from patients with autosomal dominant polycystic kidney disease. N Engl J Med 329:310\u2013313","journal-title":"N Engl J Med"},{"key":"3672_CR65","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nrneph.2014.137","volume":"10","author":"H Happe","year":"2014","unstructured":"Happe H, Peters DJ (2014) Translational research in ADPKD: lessons from animal models. Nat Rev Nephrol 10:587\u2013601","journal-title":"Nat Rev Nephrol"},{"key":"3672_CR66","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nm1004","volume":"10","author":"VE Torres","year":"2004","unstructured":"Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH 2nd (2004) Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 10:363\u2013364","journal-title":"Nat Med"},{"key":"3672_CR67","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1681\/ASN.2004121090","volume":"16","author":"X Wang","year":"2005","unstructured":"Wang X, Gattone V 2nd, Harris PC, Torres VE (2005) Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol 16:846\u2013851","journal-title":"J Am Soc Nephrol"},{"key":"3672_CR68","first-page":"R243","volume":"273","author":"F Park","year":"1997","unstructured":"Park F, Mattson DL, Skelton MM, Cowley AW Jr (1997) Localization of the vasopressin V1a and V2 receptors within the renal cortical and medullary circulation. Am J Phys 273:R243\u2013R251","journal-title":"Am J Phys"},{"key":"3672_CR69","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1681\/ASN.2013101037","volume":"25","author":"MM Rinschen","year":"2014","unstructured":"Rinschen MM, Schermer B, Benzing T (2014) Vasopressin-2 receptor signaling and autosomal dominant polycystic kidney disease: from bench to bedside and back again. J Am Soc Nephrol 25:1140\u20131147","journal-title":"J Am Soc Nephrol"},{"key":"3672_CR70","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/j.1476-5381.1992.tb09058.x","volume":"105","author":"Y Yamamura","year":"1992","unstructured":"Yamamura Y, Ogawa H, Yamashita H, Chihara T, Miyamoto H, Nakamura S, Onogawa T, Yamashita T, Hosokawa T, Mori T, Tominaga M, Yabuuchi Y (1992) Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol 105:787\u2013791","journal-title":"Br J Pharmacol"},{"key":"3672_CR71","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/(SICI)1520-6408(1999)24:3\/4<309::AID-DVG14>3.0.CO;2-5","volume":"24","author":"VH Gattone 2nd","year":"1999","unstructured":"Gattone VH 2nd, Maser RL, Tian C, Rosenberg JM, Branden MG (1999) Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease. Dev Genet 24:309\u2013318","journal-title":"Dev Genet"},{"key":"3672_CR72","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000448693","volume":"44","author":"D Zittema","year":"2016","unstructured":"Zittema D, Versteeg IB, Gansevoort RT, van Goor H, de Heer E, Veraar KA, Peters DJ, Meijer E (2016) Dose-titrated vasopressin V2 receptor antagonist improves Renoprotection in a mouse model for autosomal dominant polycystic kidney disease. Am J Nephrol 44:194\u2013203","journal-title":"Am J Nephrol"},{"key":"3672_CR73","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1093\/ndt\/gfr069","volume":"26","author":"E Meijer","year":"2011","unstructured":"Meijer E, Gansevoort RT, de Jong PE, van der Wal AM, Leonhard WN, de Krey SR, van den Born J, Mulder GM, van Goor H, Struck J, de Heer E, Peters DJ (2011) Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug. Nephrol Dial Transplant 26:2445\u20132453","journal-title":"Nephrol Dial Transplant"},{"key":"3672_CR74","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1124\/jpet.114.213256","volume":"349","author":"M Aihara","year":"2014","unstructured":"Aihara M, Fujiki H, Mizuguchi H, Hattori K, Ohmoto K, Ishikawa M, Nagano K, Yamamura Y (2014) Tolvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing increases in kidney volume and renal injury. J Pharmacol Exp Ther 349:258\u2013267","journal-title":"J Pharmacol Exp Ther"},{"key":"3672_CR75","first-page":"13","volume":"86","author":"P Upadhya","year":"2003","unstructured":"Upadhya P (2003) Models of polycystic kidney disease. Methods Mol Med 86:13\u201328","journal-title":"Methods Mol Med"},{"key":"3672_CR76","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/ng833","volume":"30","author":"CJ Ward","year":"2002","unstructured":"Ward CJ, Hogan MC, Rossetti S, Walker D, Sneddon T, Wang X, Kubly V, Cunningham JM, Bacallao R, Ishibashi M, Milliner DS, Torres VE, Harris PC (2002) The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nat Genet 30:259\u2013269","journal-title":"Nat Genet"},{"key":"3672_CR77","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0092-8674(00)81570-6","volume":"93","author":"G Wu","year":"1998","unstructured":"Wu G, D\u2019Agati V, Cai Y, Markowitz G, Park JH, Reynolds DM, Maeda Y, Le TC, Hou H Jr, Kucherlapati R, Edelmann W, Somlo S (1998) Somatic inactivation of Pkd2 results in polycystic kidney disease. Cell 93:177\u2013188","journal-title":"Cell"},{"key":"3672_CR78","doi-asserted-by":"crossref","first-page":"F1243","DOI":"10.1152\/ajprenal.00694.2013","volume":"306","author":"M Sabbatini","year":"2014","unstructured":"Sabbatini M, Russo L, Cappellaio F, Troncone G, Bellevicine C, De Falco V, Buonocore P, Riccio E, Bisesti V, Federico S, Pisani A (2014) Effects of combined administration of rapamycin, tolvaptan, and AEZ-131 on the progression of polycystic disease in PCK rats. Am J Physiol Renal Physiol 306:F1243\u2013F1250","journal-title":"Am J Physiol Renal Physiol"},{"key":"3672_CR79","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1093\/ndt\/gfr380","volume":"26","author":"O Devuyst","year":"2011","unstructured":"Devuyst O, Wang X, Serra A (2011) Vasopressin-2 receptor antagonists in autosomal dominant polycystic kidney disease: from man to mouse and back. Nephrol Dial Transplant 26:2423\u20132425","journal-title":"Nephrol Dial Transplant"},{"key":"3672_CR80","doi-asserted-by":"crossref","first-page":"F881","DOI":"10.1152\/ajprenal.00367.2004","volume":"288","author":"B Yang","year":"2005","unstructured":"Yang B, Bankir L (2005) Urea and urine concentrating ability: new insights from studies in mice. Am J Physiol Renal Physiol 288:F881\u2013F896","journal-title":"Am J Physiol Renal Physiol"},{"key":"3672_CR81","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1056\/NEJMe1006925","volume":"363","author":"T Watnick","year":"2010","unstructured":"Watnick T, Germino GG (2010) mTOR inhibitors in polycystic kidney disease. N Engl J Med 363:879\u2013881","journal-title":"N Engl J Med"},{"key":"3672_CR82","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0008-6363(01)00328-5","volume":"51","author":"L Bankir","year":"2001","unstructured":"Bankir L (2001) Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects. Cardiovasc Res 51:372\u2013390","journal-title":"Cardiovasc Res"},{"key":"3672_CR83","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1681\/ASN.2006010052","volume":"18","author":"AK Ahrabi","year":"2007","unstructured":"Ahrabi AK, Terryn S, Valenti G, Caron N, Serradeil-Le Gal C, Raufaste D, Nielsen S, Horie S, Verbavatz JM, Devuyst O (2007) PKD1 haploinsufficiency causes a syndrome of inappropriate antidiuresis in mice. J Am Soc Nephrol 18:1740\u20131753","journal-title":"J Am Soc Nephrol"},{"key":"3672_CR84","first-page":"629","volume":"53","author":"T Seeman","year":"2004","unstructured":"Seeman T, Dusek J, Vondrak K, Blahova K, Simkova E, Kreisinger J, Dvorak P, Kyncl M, Hribal Z, Janda J (2004) Renal concentrating capacity is linked to blood pressure in children with autosomal dominant polycystic kidney disease. Physiol Res 53:629\u2013634","journal-title":"Physiol Res"},{"key":"3672_CR85","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/ki.2012.225","volume":"82","author":"TA Ho","year":"2012","unstructured":"Ho TA, Godefroid N, Gruzon D, Haymann JP, Marechal C, Wang X, Serra A, Pirson Y, Devuyst O (2012) Autosomal dominant polycystic kidney disease is associated with central and nephrogenic defects in osmoregulation. Kidney Int 82:1121\u20131129","journal-title":"Kidney Int"},{"key":"3672_CR86","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016040448","author":"O Devuyst","year":"2016","unstructured":"Devuyst O, Chapman AB, Gansevoort RT, Higashihara E, Perrone RD, Torres VE, Blais JD, Zhou W, Ouyang J, Czerwiec FS (2016) Urine osmolality, response to Tolvaptan, and outcome in autosomal dominant polycystic kidney disease: results from the TEMPO 3:4 trial. J Am Soc Nephrol. doi: 10.1681\/ASN.2016040448","journal-title":"J Am Soc Nephrol"},{"key":"3672_CR87","doi-asserted-by":"crossref","first-page":"906","DOI":"10.2215\/CJN.11311111","volume":"7","author":"D Zittema","year":"2012","unstructured":"Zittema D, Boertien WE, van Beek AP, Dullaart RP, Franssen CF, de Jong PE, Meijer E, Gansevoort RT (2012) Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment. Clin J Am Soc Nephrol 7:906\u2013913","journal-title":"Clin J Am Soc Nephrol"},{"key":"3672_CR88","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1373\/clinchem.2005.060038","volume":"52","author":"NG Morgenthaler","year":"2006","unstructured":"Morgenthaler NG, Struck J, Alonso C, Bergmann A (2006) Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 52:112\u2013119","journal-title":"Clin Chem"},{"key":"3672_CR89","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrendo.2015.224","volume":"12","author":"M Christ-Crain","year":"2016","unstructured":"Christ-Crain M, Fenske W (2016) Copeptin in the diagnosis of vasopressin-dependent disorders of fluid homeostasis. Nat Rev Endocrinol 12:168\u2013176","journal-title":"Nat Rev Endocrinol"},{"key":"3672_CR90","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1210\/jc.2014-2295","volume":"99","author":"R Roussel","year":"2014","unstructured":"Roussel R, Fezeu L, Marre M, Velho G, Fumeron F, Jungers P, Lantieri O, Balkau B, Bouby N, Bankir L, Bichet DG (2014) Comparison between copeptin and vasopressin in a population from the community and in people with chronic kidney disease. J Clin Endocrinol Metab 99:4656\u20134663","journal-title":"J Clin Endocrinol Metab"},{"key":"3672_CR91","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.2215\/CJN.08690813","volume":"9","author":"D Zittema","year":"2014","unstructured":"Zittema D, van den Berg E, Meijer E, Boertien WE, Muller Kobold AC, Franssen CF, de Jong PE, Bakker SJ, Navis G, Gansevoort RT (2014) Kidney function and plasma copeptin levels in healthy kidney donors and autosomal dominant polycystic kidney disease patients. Clin J Am Soc Nephrol 9:1553\u20131562","journal-title":"Clin J Am Soc Nephrol"},{"key":"3672_CR92","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2215\/CJN.04560510","volume":"6","author":"E Meijer","year":"2011","unstructured":"Meijer E, Bakker SJ, van der Jagt EJ, Navis G, de Jong PE, Struck J, Gansevoort RT (2011) Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 6:361\u2013368","journal-title":"Clin J Am Soc Nephrol"},{"key":"3672_CR93","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1093\/ndt\/gfs070","volume":"27","author":"WE Boertien","year":"2012","unstructured":"Boertien WE, Meijer E, Zittema D, van Dijk MA, Rabelink TJ, Breuning MH, Struck J, Bakker SJ, Peters DJ, de Jong PE, Gansevoort RT (2012) Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 27:4131\u20134137","journal-title":"Nephrol Dial Transplant"},{"key":"3672_CR94","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/j.ajkd.2012.08.038","volume":"61","author":"WE Boertien","year":"2013","unstructured":"Boertien WE, Meijer E, Li J, Bost JE, Struck J, Flessner MF, Gansevoort RT, Torres VE, Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (2013) Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort. Am J Kidney Dis 61:420\u2013429","journal-title":"Am J Kidney Dis"},{"key":"3672_CR95","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1681\/ASN.2015010016","volume":"27","author":"E Cornec-Le Gall","year":"2016","unstructured":"Cornec-Le Gall E, Audrezet MP, Rousseau A, Hourmant M, Renaudineau E, Charasse C, Morin MP, Moal MC, Dantal J, Wehbe B, Perrichot R, Frouget T, Vigneau C, Potier J, Jousset P, Guillodo MP, Siohan P, Terki N, Sawadogo T, Legrand D, Menoyo-Calonge V, Benarbia S, Besnier D, Longuet H, Ferec C, Le Meur Y (2016) The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 27:942\u2013951","journal-title":"J Am Soc Nephrol"},{"key":"3672_CR96","doi-asserted-by":"crossref","first-page":"F1005","DOI":"10.1152\/ajprenal.00243.2011","volume":"301","author":"GA Reif","year":"2011","unstructured":"Reif GA, Yamaguchi T, Nivens E, Fujiki H, Pinto CS, Wallace DP (2011) Tolvaptan inhibits ERK-dependent cell proliferation, cl(\u2212) secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin. Am J Physiol Renal Physiol 301:F1005\u2013F1013","journal-title":"Am J Physiol Renal Physiol"},{"key":"3672_CR97","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1111\/j.1523-1755.2005.00703.x","volume":"68","author":"VE Torres","year":"2005","unstructured":"Torres VE (2005) Vasopressin antagonists in polycystic kidney disease. Kidney Int 68:2405\u20132418","journal-title":"Kidney Int"},{"key":"3672_CR98","unstructured":"drugs.com drug information database (2016) tolvaptan"},{"key":"3672_CR99","unstructured":"European Medicines Agency (2015) European public assessment report for Jinarc."},{"key":"3672_CR100","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/ndt\/gfv456","volume":"31","author":"RT Gansevoort","year":"2016","unstructured":"Gansevoort RT, Arici M, Benzing T, Birn H, Capasso G, Covic A, Devuyst O, Drechsler C, Eckardt KU, Emma F, Knebelmann B, Le Meur Y, Massy ZA, Ong AC, Ortiz A, Schaefer F, Torra R, Vanholder R, Wiecek A, Zoccali C, Van Biesen W (2016) Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA working groups on inherited kidney disorders and European renal best practice. Nephrol Dial Transplant 31:337\u2013348","journal-title":"Nephrol Dial Transplant"},{"key":"3672_CR101","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nrneph.2016.135","volume":"12","author":"JJ Grantham","year":"2016","unstructured":"Grantham JJ, Torres VE (2016) The importance of total kidney volume in evaluating progression of polycystic kidney disease. Nat Rev Nephrol 12:667\u2013677","journal-title":"Nat Rev Nephrol"},{"key":"3672_CR102","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2215\/CJN.03750708","volume":"4","author":"KT Bae","year":"2009","unstructured":"Bae KT, Tao C, Zhu F, Bost JE, Chapman AB, Grantham JJ, Torres VE, Guay-Woodford LM, Meyers CM, Bennett WM, Consortium for Radiologic Imaging Studies Polycystic Kidney Disease (2009) MRI-based kidney volume measurements in ADPKD: reliability and effect of gadolinium enhancement. Clin J Am Soc Nephrol 4:719\u2013725","journal-title":"Clin J Am Soc Nephrol"},{"key":"3672_CR103","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2215\/CJN.09500911","volume":"7","author":"AB Chapman","year":"2012","unstructured":"Chapman AB, Bost JE, Torres VE, Guay-Woodford L, Bae KT, Landsittel D, Li J, King BF, Martin D, Wetzel LH, Lockhart ME, Harris PC, Moxey-Mims M, Flessner M, Bennett WM, Grantham JJ (2012) Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 7:479\u2013486","journal-title":"Clin J Am Soc Nephrol"},{"key":"3672_CR104","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1681\/ASN.2013101138","volume":"26","author":"MV Irazabal","year":"2015","unstructured":"Irazabal MV, Rangel LJ, Bergstralh EJ, Osborn SL, Harmon AJ, Sundsbak JL, Bae KT, Chapman AB, Grantham JJ, Mrug M, Hogan MC, El-Zoghby ZM, Harris PC, Erickson BJ, King BF, Torres VE, Investigators CRISP (2015) Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol 26:160\u2013172","journal-title":"J Am Soc Nephrol"},{"key":"3672_CR105","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/ki.2012.8","volume":"81","author":"AB Chapman","year":"2012","unstructured":"Chapman AB (2012) The fetal environment: a critical phase that determines future renal outcomes in autosomal dominant polycystic kidney disease. Kidney Int 81:814\u2013815","journal-title":"Kidney Int"},{"key":"3672_CR106","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/ki.2011.459","volume":"81","author":"B Orskov","year":"2012","unstructured":"Orskov B, Christensen KB, Feldt-Rasmussen B, Strandgaard S (2012) Low birth weight is associated with earlier onset of end-stage renal disease in Danish patients with autosomal dominant polycystic kidney disease. Kidney Int 81:919\u2013924","journal-title":"Kidney Int"},{"key":"3672_CR107","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2215\/CJN.03780410","volume":"6","author":"MA Cadnapaphornchai","year":"2011","unstructured":"Cadnapaphornchai MA, Masoumi A, Strain JD, McFann K, Schrier RW (2011) Magnetic resonance imaging of kidney and cyst volume in children with ADPKD. Clin J Am Soc Nephrol 6:369\u2013376","journal-title":"Clin J Am Soc Nephrol"},{"key":"3672_CR108","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2215\/CJN.00550110","volume":"5","author":"JJ Grantham","year":"2010","unstructured":"Grantham JJ, Cook LT, Wetzel LH, Cadnapaphornchai MA, Bae KT (2010) Evidence of extraordinary growth in the progressive enlargement of renal cysts. Clin J Am Soc Nephrol 5:889\u2013896","journal-title":"Clin J Am Soc Nephrol"},{"key":"3672_CR109","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","volume":"371","author":"RW Schrier","year":"2014","unstructured":"Schrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Bae KT, Moore CG, Chapman AB, Trial Investigators HALT-PKD (2014) Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med 371:2255\u20132266","journal-title":"N Engl J Med"},{"key":"3672_CR110","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2215\/CJN.08350813","volume":"9","author":"MA Cadnapaphornchai","year":"2014","unstructured":"Cadnapaphornchai MA, George DM, McFann K, Wang W, Gitomer B, Strain JD, Schrier RW (2014) Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 9:889\u2013896","journal-title":"Clin J Am Soc Nephrol"},{"key":"3672_CR111","doi-asserted-by":"crossref","first-page":"972","DOI":"10.2215\/CJN.07141009","volume":"5","author":"M Gunay-Aygun","year":"2010","unstructured":"Gunay-Aygun M, Font-Montgomery E, Lukose L, Tuchman M, Graf J, Bryant JC, Kleta R, Garcia A, Edwards H, Piwnica-Worms K, Adams D, Bernardini I, Fischer RE, Krasnewich D, Oden N, Ling A, Quezado Z, Zak C, Daryanani KT, Turkbey B, Choyke P, Guay-Woodford LM, Gahl WA (2010) Correlation of kidney function, volume and imaging findings, and PKHD1 mutations in 73 patients with autosomal recessive polycystic kidney disease. Clin J Am Soc Nephrol 5:972\u2013984","journal-title":"Clin J Am Soc Nephrol"},{"key":"3672_CR112","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1542\/peds.111.5.1072","volume":"111","author":"LM Guay-Woodford","year":"2003","unstructured":"Guay-Woodford LM, Desmond RA (2003) Autosomal recessive polycystic kidney disease: the clinical experience in North America. Pediatrics 111:1072\u20131080","journal-title":"Pediatrics"},{"key":"3672_CR113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.md.0000200165.90373.9a","volume":"85","author":"M Adeva","year":"2006","unstructured":"Adeva M, El-Youssef M, Rossetti S, Kamath PS, Kubly V, Consugar MB, Milliner DM, King BF, Torres VE, Harris PC (2006) Clinical and molecular characterization defines a broadened spectrum of autosomal recessive polycystic kidney disease (ARPKD). Medicine (Baltimore) 85:1\u201321","journal-title":"Medicine (Baltimore)"},{"key":"3672_CR114","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12882-015-0002-z","volume":"16","author":"K Ebner","year":"2015","unstructured":"Ebner K, Feldkoetter M, Ariceta G, Bergmann C, Buettner R, Doyon A, Duzova A, Goebel H, Haffner D, Hero B, Hoppe B, Illig T, Jankauskiene A, Klopp N, Konig J, Litwin M, Mekahli D, Ranchin B, Sander A, Testa S, Weber LT, Wicher D, Yuzbasioglu A, Zerres K, Dotsch J, Schaefer F, Liebau MC, ESCAPE Study Group; GPN Study Group (2015) Rationale, design and objectives of ARegPKD, a European ARPKD registry study. BMC Nephrol 16:22","journal-title":"BMC Nephrol"},{"key":"3672_CR115","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3389\/fped.2014.00068","volume":"2","author":"MC Liebau","year":"2014","unstructured":"Liebau MC (2014) An emerging molecular understanding and novel targeted treatment approaches in pediatric kidney diseases. Front Pediatr 2:68","journal-title":"Front Pediatr"},{"key":"3672_CR116","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/hep.26140","volume":"58","author":"TV Masyuk","year":"2013","unstructured":"Masyuk TV, Radtke BN, Stroope AJ, Banales JM, Gradilone SA, Huang B, Masyuk AI, Hogan MC, Torres VE, Larusso NF (2013) Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases. Hepatology 58:409\u2013421","journal-title":"Hepatology"},{"key":"3672_CR117","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/nep.12211","volume":"19","author":"TM Myint","year":"2014","unstructured":"Myint TM, Rangan GK, Webster AC (2014) Treatments to slow progression of autosomal dominant polycystic kidney disease: systematic review and meta-analysis of randomized trials. Nephrology (Carlton) 19:217\u2013226","journal-title":"Nephrology (Carlton)"},{"key":"3672_CR118","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1038\/ki.2014.427","volume":"87","author":"S Tao","year":"2015","unstructured":"Tao S, Kakade VR, Woodgett JR, Pandey P, Suderman ED, Rajagopal M, Rao R (2015) Glycogen synthase kinase-3beta promotes cyst expansion in polycystic kidney disease. Kidney Int 87:1164\u20131175","journal-title":"Kidney Int"},{"key":"3672_CR119","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1093\/jmcb\/mjw022","volume":"8","author":"VR Kakade","year":"2016","unstructured":"Kakade VR, Tao S, Rajagopal M, Zhou X, Li X, Yu AS, Calvet JP, Pandey P, Rao R (2016) A cAMP and CREB-mediated feed-forward mechanism regulates GSK3beta in polycystic kidney disease. J Mol Cell Biol 8:464\u2013476","journal-title":"J Mol Cell Biol"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-017-3672-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-017-3672-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-017-3672-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:52:46Z","timestamp":1658969566000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-017-3672-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,28]]},"references-count":119,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["3672"],"URL":"https:\/\/doi.org\/10.1007\/s00467-017-3672-x","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,28]]}}}